Merlin benefits from sustained biotech optimism
The biotechnology investor has held a first close at E125m for its third Biosciences fund, targeting a final close next year at E250m.
30 December 2012•2 mins read
The biotechnology investor has held a first close at E125m for its third Biosciences fund, targeting a final close next year at E250m.
Succession: Why waiting too long can price out the next generation
22 October 2026 · 5 mins read
Side Letter: 15,000's a crowd
22 October 2026 · 3 mins read
HK's Sun Hung Kai & Co ramps up PE pacing as liquidity improves
22 October 2026 · 5 mins read
Hamilton Lane's Hirsch: Private markets industry has too many GPs
22 October 2026 · 1 min read
Defence funds flood Europe, though mid-market remains ‘largely untouched’
21 October 2026 · 4 mins read
Side Letter: Walking the talk
21 October 2026 · 5 mins read
Number Crunch: Private equity’s AI uptake
20 October 2026 · 3 mins read
